Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2019-11-18 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is very short (1811 characters) and explicitly states, 'Attached hereto is a report on *pressrelease111619_isa.pdf*'. This structure—a brief filing announcing the availability of an attached report (likely a press release or regulatory filing)—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), according to Rule 2 (The 'MENU VS MEAL' Rule). Since it references the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE) and uses the header 'Immediate Report Regulation 4...', it is a formal regulatory announcement. Given the specific mention of attaching a report/press release rather than containing the full content of a major report (like 10-K or IR), RPA is the most precise fit, as it announces the publication of another document.
2019-11-18 English
Report of Periodic or Interim Report
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains unaudited condensed consolidated financial statements for the three and nine-month periods ended September 30, 2019. Since it provides comprehensive financial statements for an interim period (less than a full fiscal year) and is not merely an announcement or certification, it is classified as an Interim/Quarterly Report. 9M 2019
2019-11-14 English
Report of Periodic or Interim Report
Report Publication Announcement Classification · 1% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed under Israeli Securities Authority regulations. Crucially, it mentions 'Attached hereto is a report on *6-k*'. A Form 6-K is a report filed by foreign private issuers with the SEC to report material events that occur between annual report filings. Since this document is an announcement *about* an attached periodic/interim report (6-K) and is very short (1879 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) itself. The filing date is 14/11/2019, indicating a periodic disclosure.
2019-11-14 English
Immediate Report
Investor Presentation Classification · 1% confidence The document is a press release from Enlivex Therapeutics announcing that company management will make a corporate presentation and host 1x1 meetings at the 10th Annual Jefferies 2019 London Healthcare Conference. This type of announcement, detailing participation in an external industry conference where management will present company updates, aligns best with an Investor Presentation (IP) or a general announcement about investor engagement. Since the core purpose is to inform the market about management's upcoming presentation at a specific investor-focused conference, 'Investor Presentation' (IP) is the most fitting category, as it often covers the material that would be presented. It is not a formal regulatory filing like 10-K or ER, nor is it a transcript or a formal report.
2019-11-12 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is very short (1811 characters) and explicitly states, "Attached hereto is a report on *pressrelease111219_isa.pdf*". This structure—a brief filing announcing the availability of a separate, attached report (likely a press release or regulatory filing)—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. It is not the full report itself (like 10-K or IR). The filing is made to the Israel Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE) under 'Immediate Report Regulation 4'. Since RPA is a specific category for such announcements, it is preferred over the general fallback RNS.
2019-11-12 English
Immediate Report
Earnings Release Classification · 1% confidence The document is a press release from Enlivex Therapeutics announcing 'Positive Interim Safety and Efficacy Data' from an ongoing clinical trial for their drug Allocetra in severe sepsis patients. It details specific clinical outcomes (mortality rates, SOFA scores) in a comparative table format and includes commentary from company executives. This structure—announcing preliminary or interim results of financial/operational performance (clinical trial data in this case) before a full report—is characteristic of an Earnings Release (ER) or a general announcement of significant operational news. Since it is not a full annual report (10-K), a comprehensive interim report (IR), a transcript (CT), or a formal regulatory filing announcement (RPA/RNS), the most appropriate classification for the initial release of key performance indicators (even clinical ones) is Earnings Release (ER), as it serves to inform the market of recent operational achievements. Q4 2019
2019-11-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.